Related Experiment Video
Updated: May 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS
1Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA, cvpollack@gmail.com.
Insights
Parenteral anticoagulation is essential for acute coronary syndrome (ACS) management. Switching anticoagulant agents during ACS care offers no benefit and may increase bleeding risk.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Anticoagulation with parenteral antithrombin agents is a cornerstone in the initial treatment of acute coronary syndrome (ACS).
- While antiplatelet strategies are debated, the necessity of acute anticoagulation in ACS is undisputed.
Purpose of the Study:
- To review the foundational role of anticoagulation in acute coronary syndrome (ACS) management.
- To discuss agent selection based on patient management (medical vs. interventional), ischemic risk, and hemorrhagic risk.
Main Methods:
- Review of clinical trial data and established guidelines for anticoagulation in ACS.
- Analysis of factors influencing the choice of anticoagulant agents.
Main Results:
- Clinical trials indicate that switching anticoagulant agents during ACS treatment provides no additional efficacy.
- Switching agents may elevate the risk of bleeding complications in ACS patients.
Conclusions:
- Acute anticoagulation is a critical component of ACS care, often initiated in the emergency department.
- Current evidence suggests maintaining a consistent anticoagulant agent throughout ACS management is advisable to avoid potential harm.
Opinion Statement:
Anticoagulation with a parenteral (intravenous or subcutaneous) antithrombin agent is foundational to the early management of acute coronary syndrome (ACS). While indications for, the timing of, and the choice among agents (other than aspirin) that provide antiplatelet effects are all subject to discussion, the need for acute anticoagulation is beyond question. There are a number of agents that can be used for anticoagulation in ACS, depending upon the intended near-term management of the patient (medical vs interventional), the patient's ischemic risk, and the patient's hemorrhagic risk. It is usually appropriate for therapy to be initiated in the emergency department (ED), which in turn supports close collaboration between "upstream" providers and interventional cardiologists. Clinical trial data suggest that "switching" agents during ACS care affords no efficacy advantage and may increase bleeding risk. At least 1 potential new agent (otamixaban) that can be used in all ACS care settings is on the near-term horizon, with the drug currently in late Phase III testing.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome V: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

